Gastrointestinal malignancies represent a common and heterogeneous group of tumors and account for a high percentage of adult cancers. Over the past decades, early detection, advanced endoscopy and surgery, along with the additional benefit in some cases from perioperative treatment, have led to improved outcomes in localized disease.
Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
The series “GI Malignancies and Immunotherapy” was commissioned by the editorial office, Translational Gastroenterology and Hepatology without any sponsorship or funding. Khaldoun Almhanna served as the unpaid Guest Editor for the series.